Embecta Corp. announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system. embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.